ASCO GI 2023 Zolbetuximab plus chemotherapy prolongs survival in CLDN18.2+/HER2- gastric/GEJ adenocarcinoma Read more
ASCO 2022 COVID-19 pandemic impacted on screening and care of patients with rare hereditary cancers Read more
ELCC 2022 Sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metast... Read more
ELCC 2022 Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutated lung adenocarci... Read more
ELCC 2022 Savolitinib in the treatment of patients with non-small cell lung cancer and MET exon 14 skipp... Read more
ASCO GI 2022 Combination of docetaxel, cisplatin and 5-FU as a new standard neoadjuvant treatment for oesop... Read more
